U.S. markets closed

Idera Pharmaceuticals, Inc. (IDRA)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.2902-0.0099 (-3.30%)
At close: 03:59PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected


Previous Close0.3001
Bid0.2929 x 1800
Ask0.2995 x 800
Day's Range0.2880 - 0.3000
52 Week Range0.2700 - 0.9500
Avg. Volume103,550
Market Cap18.096M
Beta (5Y Monthly)1.35
PE Ratio (TTM)N/A
EPS (TTM)-0.4420
Earnings DateNov 14, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for IDRA

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Idera Pharmaceuticals, Inc.
    Daily – Vickers Top Buyers & Sellers for 06/04/2021The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Fair Value
    Economic Moat
    2 years agoArgus Research
View more
  • GlobeNewswire

    Idera Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

    EXTON, Pa. and DURHAM, N.C., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera,” the “Company,” “we,” “us,” or “our”) (Nasdaq: IDRA) today reported its consolidated financial and operational results for the third quarter ended September 30, 2022. “We are pleased to have completed the merger of Idera and Aceragen at the end of the third quarter, better enabling us to deliver important therapies for people living with rare diseases,” stated John Taylor, Idera’s Chief Executive

  • Benzinga

    Idera Pharma Acquires Rare Disease Player, Names New CEO

    Idera Pharmaceuticals Inc (NASDAQ: IDRA) acquired Aceragen Inc, a privately-held biotechnology company focused on rare, orphan pulmonary, and rheumatic diseases. The combined cash of the two companies is expected to provide a runway into Q3 2023, funding the advancement of Aceragen's pipeline, including ACG-701 and ACG-801, through important 2023 clinical milestones. The company estimates an annual peak sales potential of $650 million from the three current lead programs. Vincent Milano, Idera's

  • GlobeNewswire

    Idera Pharmaceuticals Acquires Aceragen

    Acquisition includes late-stage rare disease portfolio with anticipated 2023 clinical milestones and first potential product approval as early as late 2024 Conference call and webcast today at 5:00 p.m. ET EXTON, Pa. and DURHAM, N.C., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera,” the “Company,” “we,” “us,” or “our”) (Nasdaq: IDRA) today announced it has completed the acquisition of Aceragen, Inc. (“Aceragen”), a privately-held biotechnology company addressing rare, orp